US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long NVO ETF

16.04

+1.097.29%

Post-market: 15.98-0.0600-0.37%19:48 EDT

Volume:336.58K

Turnover:5.28M

Market Cap:41.51M

PE:- -

High:16.04

Open:15.50

Low:15.36

Close:14.95

52wk High:36.00

52wk Low:9.23

Shares:2.59M

Float Shares:2.59M

Volume Ratio:0.88

T/O Rate:13.00%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Novo Nordisk (NVO) Stock May Trade Below Fair Value Despite Obesity Market Lawsuit

Simply Wall St.

Novo Nordisk A/S Stock (NVO) Closed Up by 3.71% on Aug 25: A Full Analysis

More US Employers to Drop Weight-Loss Drugs in 2027, as Healthcare Costs Increase

Novo Nordisk price target raised to DKK 275 from DKK 250 at JPMorgan

Novo Nordisk call volume above normal and directionally bullish

Novo Nordisk Sales Growth Could Remain Flat This Year

Novo Nordisk (0QIU) Receives a Hold from Deutsche Bank

J.P. Morgan Sticks to Its Hold Rating for Novo Nordisk (0QIU)

Novo Nordisk’s AMAZE 9 Oral Obesity Trial: A New Pill in the Weight-Loss Race

Novo Nordisk A/S Series B Stock Falls Monday, Underperforms Market

Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk

Lexicon earns third $10M milestone payment from Novo Nordisk for LX9851

Hong Kong Memory Chip Stocks Plunge as Samsung Drops Nearly 8%, Leveraged Product Sinks 16%

South Korea Sees Surge in Seized Illegal Weight-Loss Drugs, Tripling Last Year's Total in Just Six Months

Novo Nordisk A/S Series B Stock Rises Friday, Outperforms Market

Novonesis Expects Results from Weight-Loss Drug Supplement Study in 2027

Moderately bullish activity in Novo Nordisk with shares up 1.32%

Novo Nordisk Adds a New Early-Stage Obesity Drug to Its Pipeline

Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/NVOX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"Defiance Daily Target 2X Long NVO ETF","latestPrice":16.04,"timestamp":1787688000000,"preClose":14.95,"halted":0,"volume":336578,"hourTrading":{"tag":"盘后","latestPrice":15.98,"preClose":16.04,"latestTime":"19:48 EDT","volume":1692,"amount":27162.02,"timestamp":1787701730453,"change":-0.06,"changeRate":-0.003741,"amplitude":0.006141},"delay":0,"changeRate":0.07290969899665552,"floatShares":2588101,"shares":2588101,"eps":0,"marketStatus":"Not Yet Opened","change":1.09,"latestTime":"08-25 16:00:00 EDT","open":15.5,"high":16.04,"low":15.355,"amount":5277145.541382,"amplitude":0.045819,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":14.95,"sharesOutstanding":4098101,"nav":14.94,"aum":38666228.94,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":15.4,"preClose":14.95,"latestTime":"08:58 EDT","volume":539,"amount":8293.227558,"timestamp":1787662714608,"change":0.45,"changeRate":0.0301,"amplitude":0.007358},"postHourTrading":{"tag":"盘后","latestPrice":15.98,"preClose":16.04,"latestTime":"19:48 EDT","volume":1692,"amount":27162.02,"timestamp":1787701730453,"change":-0.06,"changeRate":-0.003741,"amplitude":0.006141},"volumeRatio":0.878296,"impliedVol":0.6386,"impliedVolPercentile":0.1124},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":2588101,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.878296,"shares":2588101,"dividePrice":0,"high":16.04,"amplitude":0.045819,"preClose":14.95,"low":15.355,"week52Low":9.23,"pbRate":"--","week52High":36,"institutionHeld":0,"latestPrice":16.04,"eps":0,"divideRate":0,"volume":336578,"delay":0,"ttmEps":0,"open":15.5,"prevYearClose":21.89,"prevWeekClose":14.83,"prevMonthClose":15.035,"prevQuarterClose":16.05,"fiveDayClose":14.205,"twentyDayClose":17.79,"sixtyDayClose":14.95},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662555765","title":"Novo Nordisk (NVO) Stock May Trade Below Fair Value Despite Obesity Market Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2662555765","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662555765?lang=en_us&edition=fundamental","pubTime":"2026-08-26 07:30","pubTimestamp":1787700658,"startTime":"0","endTime":"0","summary":"Novo Nordisk stock combines a weak three year share price record with valuation checks that still lean supportive, which raises questions about how much pessimism is already reflected in today’s price.\n\nOver the past three years the share price has declined 45.7%, which suggests investors have meaningfully reset their expectations for the business.\nExpectations around Novo Nordisk’s ability to grow and defend its position in the obesity treatment market can support the investment case. At the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nvo-stock-may-trade-below-fair-value-despite-ob","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/novo-nordisk-nvo-stock-may-trade-below-fair-value-despite-ob","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4599","NVOC","THNR","OZEM","IE00BZ1G4Q59.USD","BK4588","LU0154236417.USD","BK4007","LU1093756168.USD","NVO","NVOX","NVOH","IE00BKVL7J92.USD","PPH","BK4532","LU1093756325.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662526917","title":"Novo Nordisk A/S Stock (NVO) Closed Up by 3.71% on Aug 25: A Full Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2662526917","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662526917?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:15","pubTimestamp":1787688927,"startTime":"0","endTime":"0","summary":"• Wall Street raised Novo Nordisk price targets and long-term financial forecasts.\n• Strong GLP-1 therapy adoption and share buybacks bolster market confidence.\n• The company reports $46.70B in annual revenue and $15.48B in net profit.","market":"sg","thumbnail":"https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262131293-market-movers-nvo-20260825","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","LU1093756168.USD","BK4007","LU0154236417.USD","LU1093756325.SGD","BK4588","THNR","IE00BZ1G4Q59.USD","BK4585","NVOC","OZEM","NVOH","IE00BKVL7J92.USD","BK4532","BK4599","PPH","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662375970","title":"More US Employers to Drop Weight-Loss Drugs in 2027, as Healthcare Costs Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2662375970","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662375970?lang=en_us&edition=fundamental","pubTime":"2026-08-26 02:04","pubTimestamp":1787681049,"startTime":"0","endTime":"0","summary":"UPDATE 1-More US employers to drop weight-loss drugs in 2027, as healthcare costs increaseNEW YORK, Aug 25 (Reuters)-About 14% of employers in the United States have already or plan to drop GLP-1 drug","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M0K5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","IE00BK4W5M84.HKD","IE00B4R5TH58.HKD","LU0225283273.USD","LU0289739699.SGD","THNR","IE00B7KXQ091.USD","LU0820561909.HKD","SG9999013999.USD","SG9999015986.USD","LU0385154629.USD","LU0820561818.USD","IE00BJT1NW94.SGD","MEDX","LU2028103732.USD","IE00BKPKM429.USD","LU2462157665.USD","IE00B4JS1V06.HKD","BK4007","LU1917777945.USD","TRUH","ELIS","LU0256863902.USD","SG9999015978.USD","LU0683600562.USD","LU0882574139.USD","IE00BFSS8Q28.SGD","SG9999014898.SGD","LU1064131342.USD","CANC","LU1804176565.USD","LU0174119429.USD","IE00BFTCPJ56.SGD","LU2168564495.EUR","LU0689472784.USD","LU1023059063.AUD","BK4581","IE0005OL40V9.USD","MHIP","LU2106854487.HKD","BK4599","LU0708995401.HKD","IE00BZ1G4Q59.USD","LU2361044865.SGD","IE00BWXC8680.SGD","IE00BN29S564.USD","ILDR","LU0345770993.USD","LU2111349929.HKD","LU0456855351.SGD","LU0133085943.USD","LU0889565916.HKD","LU0323591593.USD","LU1712237335.SGD","LU2264538146.SGD","SG9999014906.USD","LU2168564149.EUR","LU0006306889.USD","LU0672654240.SGD","LU0079474960.USD","IE0004445015.USD","LU0097036916.USD","LU1720051108.HKD","NVO","LU0154236417.USD","IYH","LU2168564065.EUR","LU0106261372.USD","VHT","LU1629891620.HKD","HRTS","IE00B2B36J28.USD","IE00BJLML261.HKD","ELIL","FTXH","IE00BJJMRY28.SGD","LU0943347566.SGD","LU0316494557.USD","LU1691799644.USD","BK4532","LU2168564222.USD","LU1057294990.SGD","JDOC","BK4588","LU0061475181.USD","SGXZ81514606.USD","IE0001KFT4U8.USD","LU2471134796.USD","XLV","LU2750360641.GBP","LU1979441026.SGD","LU1267930730.SGD","LU2023250330.USD","LU0354030511.USD","LU2324357040.USD","SG9999015952.SGD","SG9999015945.SGD","LU2112291526.USD","SG9999017495.SGD","LU0882574055.USD","LU2271345857.HKD","LU1868836914.USD","LU2213496289.HKD","LU0158827948.USD","NVOX","LU1069344957.HKD","LU0417517546.SGD","LU1983299246.USD","IE00BFSS7M15.SGD","LU0256863811.USD","IE00BJJMRX11.SGD","LU0820562030.AUD","LU1720051017.SGD","LU2087625088.SGD","LU2491049909.HKD","LU2756315318.SGD","SGXZ99366536.SGD","LLYZ","LU0210536198.USD","LU2265009873.SGD","LU2023251221.USD","LU2896262040.SGD","LU1093756168.USD","LU1868836591.USD","LU2491050154.USD","LU2237443549.SGD","SG9999001176.SGD","IE00B1BXHZ80.USD","LU2756315664.SGD","LU0096364046.USD","IE0004445239.USD","BK4585","LU1814569148.SGD","GB00BDT5M118.USD","IXJ","WDNA","LU0198837287.USD","LU2108987350.USD","LU0122379950.USD","LU2063271972.USD","BK4516","LLII","LU2089284900.SGD","IE0009355771.USD","IE00BKVL7J92.USD","LLY","LU0109394709.USD","LU2237443978.SGD","LU2552382132.HKD","LU1061106388.HKD","LU2746668461.USD","SGXZ57979304.SGD","LU2168563687.JPY","LU2746668974.SGD","LU2361045086.USD","LU0094547139.USD","NVOC","LU2089283258.USD","LU1974910355.USD","NVOH","LU2211815571.USD","LU0114720955.EUR","LLYX","LU1232071149.USD","LU2237438978.USD","LU0158827781.USD","LU1989771016.USD","OZEM","BK4534","LU1551013342.USD","LU1988902786.USD","LU0466842654.USD","MEDI","LU1280957306.USD","LU1323610961.USD","LU1366192091.USD","IE00BJJMRZ35.SGD","LU2237443382.USD","LU2602419157.SGD","GDOC","SG9999018857.SGD","FHLC","LU2237443622.USD","PPH","LU1868836757.USD","LU2456880835.USD","LU0823434740.USD","SG9999014914.USD","TMED","IE00B1XK9C88.USD","LU0471298777.SGD","LU2462591350.SGD","LU1548497426.USD","IE00BKDWB100.SGD","CURE","LU2750360997.AUD","PJP","LU0823434583.USD","LU0471298694.HKD","LU0786609619.USD","LU0353189763.USD","LU2089984988.USD","LU0266013472.USD","LU1145028129.USD","LU2471134523.USD","IE00BK4W5L77.USD","LU1127390331.HKD","LU2237443465.HKD","RXL","LU0787776722.HKD","LU1035775433.USD","LU2491050071.SGD","LU2237443895.HKD","LU0823416689.USD","SG9999001176.USD","LU2361044949.HKD","LU2552382058.USD","LU0354030438.USD","LU0203201768.USD","LU2468319806.SGD","LU0353189680.USD","LU2360106947.USD","LU2552382215.SGD","LU0058720904.USD","LU0640476718.USD","SGXZ51526630.SGD","LU2236285917.USD","SGXZ31699556.SGD","LU2471134952.CNY","IHE","LU1551013425.SGD","LU2417539215.USD","SG9999014880.SGD","LU1868837300.USD","LU2461242641.AUD","LU0109391861.USD","LU0320765992.SGD","LU0234572021.USD","LU1623119135.USD","LU0964807845.USD","AGNG","IE0002141913.USD","LU1093756325.SGD","LU2357305700.SGD","LU2471134879.HKD","LU0345770308.USD","SG9999018865.SGD","LU1868837136.USD","LU2023250504.SGD","LU0320765059.SGD","LU1291159041.SGD","LU0432979614.USD","LU0203202063.USD","IE00B775H168.HKD","LU0238689110.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662275688","title":"Novo Nordisk price target raised to DKK 275 from DKK 250 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2662275688","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662275688?lang=en_us&edition=fundamental","pubTime":"2026-08-26 00:00","pubTimestamp":1787673628,"startTime":"0","endTime":"0","summary":"JPMorgan raised the firm’s price target on Novo Nordisk (NVO) to DKK 275 from DKK 250 and keeps a Neutral rating on the shares. Published first on ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-price-target-raised-to-dkk-275-from-dkk-250-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-price-target-raised-to-dkk-275-from-dkk-250-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE00BZ1G4Q59.USD","BK4532","LU1093756168.USD","NVOX","LU1093756325.SGD","IE00BKVL7J92.USD","BK4599","PPH","BK4588","NVOC","LU0154236417.USD","THNR","OZEM","NVO","BK4007","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662756880","title":"Novo Nordisk call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2662756880","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662756880?lang=en_us&edition=fundamental","pubTime":"2026-08-25 23:50","pubTimestamp":1787673015,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Novo Nordisk (NVO) with 24,990 calls trading, 1.1x expected, and implied vol increasing over 2 points to 34.74%. Oc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-call-volume-above-normal-and-directionally-bullish-thefly-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-call-volume-above-normal-and-directionally-bullish-thefly-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVOH","OZEM","LU0154236417.USD","NVOX","LU1093756325.SGD","NVO","NVOC","THNR","LU1093756168.USD","BK4007","BK4585","PPH","BK4599","BK4532","BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662732870","title":"Novo Nordisk Sales Growth Could Remain Flat This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2662732870","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662732870?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:33","pubTimestamp":1787661180,"startTime":"0","endTime":"0","summary":"1233 GMT - Novo Nordisk's sales growth could be flat this year, J.P. Morgan says. The Danish drugmaker recently raised its guidance and now forecasts sales growth ranging from flat to minus 6%. The bank raises its 2026 sales forecasts by 5%, largely due to higher forecasts for diabetes and weight-loss drugs Ozempic and Wegovy, partially offset by slowing launch momentum of oral Wegovy in the U.S. Novo Nordisk's top-line could still see modest 1% growth in 2027, JPM says. The bank expects 2% sales growth in 2028, with any further acceleration largely dependent on the successful development of zenagamtide, particularly in the oral format, which could have the highest weight loss of any of the oral drugs. JPM retains its neutral rating for the stock and lifts its price target to 275 Danish kroner from 250 kroner. Shares rise 2.2% to 305.80 kroner.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","IE00BN8TJ469.HKD","BK4550","LU0265550946.USD","LU1116320901.HKD","BK4581","LU2357305700.SGD","LU1914381329.SGD","LU2430703251.USD","NVO","LU1261432733.SGD","THNR","VFH","IE0034235303.USD","LU2430703095.HKD","LU0820561818.USD","LU0345769128.USD","LU0496365809.HKD","LU1032466523.USD","IE00BKDWB100.SGD","BK4207","IXG","IE00BJLML261.HKD","IE00BLSP4452.SGD","IE00BZ1G4Q59.USD","IE00BJTD4N35.SGD","LU2106854487.HKD","LU2381873111.SGD","LU0310799852.SGD","IE00BJTD4V19.USD","IE00BK4W5M84.HKD","LU2236285917.USD","BK4504","LU2746668461.USD","UYG","LU2462157665.USD","LU2505996509.AUD","LU0345769631.USD","BK4599","IE000M9KFDE8.USD","LU0203345920.USD","BK4566","LU1116320737.USD","LU0320765646.SGD","LU1974910355.USD","SG9999002224.SGD","LU0251132253.USD","LU1496350171.SGD","LU2552382058.USD","LU1629891620.HKD","LU2054465674.USD","IE00B3S45H60.SGD","IE00BKVL7J92.USD","LU1244550577.SGD","LU1720051017.SGD","LU0211328371.USD","IE0034235188.USD","LU1064131342.USD","LU0640476718.USD","LU0256863902.USD","NVOC","LU0971096721.USD","LU1119994496.HKD","BK4533","BK4588","LU2746668974.SGD","LU1244550494.USD","LU0820561909.HKD","LU1551013425.SGD","LU2023250330.USD","LU0238689110.USD","LU1548497426.USD","LU1720051108.HKD","LU0323591593.USD","LU0006306889.USD","LU2244417387.USD","XLF","LU0208291251.USD","PPH","LU0868494617.USD","LU2211815571.USD","BK4534","LU2237443465.HKD","IE00B1XK9C88.USD","LU0211326839.USD","LU0964807845.USD","LU2237443895.HKD","JPM","LU1267930490.SGD","LU1668664300.SGD","IE00BLSP4239.USD","JPMO","LU1366192091.USD","LU0070302665.USD","LU0211326755.USD","LU0234570918.USD","LU1093756325.SGD","LU0215105999.USD","IE0034235295.USD","LU0345770308.USD","LU0048584097.USD","LU0154236417.USD","IYG","OZEM","LU0689472784.USD","LU1280957306.USD","LU2237443549.SGD","LU0943347566.SGD","LU2756315664.SGD","NVOX","LU0942090050.USD","LU1894683348.USD","LU0320765489.SGD","IE00BFXG1179.USD","LU1670628061.USD","JPO","IE00B1BXHZ80.USD","LU0187121727.USD","IE00BK4W5L77.USD","LU0267386448.USD","LU0882574139.USD","LU1496350502.SGD","TRUF","SG9999002232.USD","LU2023250504.SGD","LU1988902786.USD","LU0106261372.USD","IYF","LU0203347892.USD","LU2023250843.SGD","LU2756315318.SGD","LU0234572021.USD","LU0787776722.HKD","LU2237443622.USD","LU2237443382.USD","BK4007","IE00BDRTCR15.USD","LU2237443978.SGD","LU0265550359.USD","BK4516","IE00BYXW3230.USD","LU1162221912.USD","LU2430703178.SGD","LU1244550221.USD","LU0211327993.USD","LU2417539215.USD","LU0345770993.USD","IE00BHPRN162.USD","BK4585","KBWB","LU0976567544.SGD","LU1363072403.SGD","IE00BDCRKT87.USD","LU1670627923.USD","LU0256863811.USD","LU1084165304.USD","LU0859254822.USD","NVOH","LU0149725797.USD","LU0170899867.USD","LU2592432038.USD","LU2456880835.USD","TFNS","FNCL","LU2552382215.SGD","BK4532","LU2552382132.HKD","IE00BBT3K403.USD","LU0868494708.USD","LU1145028129.USD","FTXO","LU0683600562.USD","LU2264538146.SGD","LU1551013342.USD","LU0211331839.USD","IE00B775SV38.USD","LU2505996681.GBP","IE00BWXC8680.SGD","LU0820562030.AUD","LU1894683264.USD","LU0417517546.SGD","LU1093756168.USD","LU2242649171.HKD","LU2357627491.SGD","LU2213496289.HKD","LU0106831901.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662782002","title":"Novo Nordisk (0QIU) Receives a Hold from Deutsche Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2662782002","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662782002?lang=en_us&edition=fundamental","pubTime":"2026-08-25 16:36","pubTimestamp":1787646964,"startTime":"0","endTime":"0","summary":"Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Novo Nordisk today and set a price target of DKK290.00. According to TipRanks,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/novo-nordisk-0qiu-receives-a-hold-from-deutsche-bank-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/novo-nordisk-0qiu-receives-a-hold-from-deutsche-bank-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4588","LU1093756325.SGD","NVOC","LU1093756168.USD","NVOX","LU0154236417.USD","BK4007","PPH","NVOH","OZEM","THNR","NVO","BK4599","BK4585","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662845387","title":"J.P. Morgan Sticks to Its Hold Rating for Novo Nordisk (0QIU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662845387","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662845387?lang=en_us&edition=fundamental","pubTime":"2026-08-25 15:25","pubTimestamp":1787642723,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novo Nordisk today and set a price target of DKK275.00. According to TipRanks, Vosse...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-its-hold-rating-for-novo-nordisk-0qiu-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-its-hold-rating-for-novo-nordisk-0qiu-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756325.SGD","IE00BKVL7J92.USD","BK4585","BK4532","IE00BZ1G4Q59.USD","NVO","NVOX","LU0154236417.USD","BK4599","LU1093756168.USD","OZEM","BK4588","PPH","NVOC","THNR","BK4007","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662270747","title":"Novo Nordisk’s AMAZE 9 Oral Obesity Trial: A New Pill in the Weight-Loss Race","url":"https://stock-news.laohu8.com/highlight/detail?id=2662270747","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662270747?lang=en_us&edition=fundamental","pubTime":"2026-08-25 00:31","pubTimestamp":1787589070,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S (NVO) has launched AMAZE 9, a Phase 3 obesity study title...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-amaze-9-oral-obesity-trial-a-new-pill-in-the-weight-loss-race?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-amaze-9-oral-obesity-trial-a-new-pill-in-the-weight-loss-race?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","IE00BKVL7J92.USD","BK4007","NVO","IE00BZ1G4Q59.USD","BK4599","LU0154236417.USD","NVOC","BK4585","BK4588","NVOX","NVOH","LU1093756168.USD","OZEM","THNR","LU1093756325.SGD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662270631","title":"Novo Nordisk A/S Series B Stock Falls Monday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2662270631","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662270631?lang=en_us&edition=fundamental","pubTime":"2026-08-25 00:02","pubTimestamp":1787587320,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B dropped 0.5% to DKK299.25 Monday on what proved to be an overall unfavorable trading session for the stock market, with the OMX Nordic 40 Index falling 0.3% to 2,710.02.The company closed DKK110.70 below its 52-week high of DKK409.95, which the company reached on January 23, 2026.Trading volume was 3,241,705, compared to the 50-day average trading volume of 4,317,428.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NVOH","THNR","OZEM","PPH","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4599","LU1093756168.USD","LU1093756325.SGD","NVOX","BK4585","BK4007","NVO","NVOC","IE00BKVL7J92.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661727717","title":"Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme","url":"https://stock-news.laohu8.com/highlight/detail?id=2661727717","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661727717?lang=en_us&edition=fundamental","pubTime":"2026-08-24 23:18","pubTimestamp":1787584692,"startTime":"0","endTime":"0","summary":"Novo Nordisk ( ($NVO) ) has issued an announcement. On 6 May 2026, Novo Nordisk launched a share repurchase programme under EU Safe Harbour rules a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-details-progress-in-dkk-15-billion-share-buyback-programme-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-details-progress-in-dkk-15-billion-share-buyback-programme-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","NVOH","IE00BKVL7J92.USD","NVO","LU0154236417.USD","BK4532","IE00BZ1G4Q59.USD","OZEM","BK4585","NVOX","BK4588","PPH","NVOC","BK4007","LU1093756168.USD","LU1093756325.SGD","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271595","title":"Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271595","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271595?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:12","pubTimestamp":1787577120,"startTime":"0","endTime":"0","summary":"Lexicon Pharmaceuticals has earned a third $10 million milestone payment from Novo Nordisk for hitting a key milestone in the clinical development program for its obesity drug.The biopharmaceutical company on Monday said that it has achieved a patient dosing milestone in the continuing phase 1 program for LX9851, a treatment being developed for obesity and associated metabolic disorders.Lexicon and Novo Nordisk signed an exclusive worldwide license agreement for LX9851 last year, under which Novo Nordisk is able to develop, manufacture and commercialize the drug for all indications.So far, Lexicon has earned $75 million of the $1 billion in potential upfront, development, regulatory and commercial milestone payments available under its Novo Nordisk collaboration. Lexicon is also entitled to receive tiered royalties on future LX9851 sales.The development program for LX9851 was kicked off by Novo Nordisk in March to investigate the safety, tolerability, pharmacokinetics and pharmacodynam","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LXRX","LU1093756168.USD","THNR","BK4007","NVOC","BK4532","BK4139","NVOX","NVO","NVOH","OZEM","LU0154236417.USD","PPH","LU1093756325.SGD","BK4599","IE00BKVL7J92.USD","BK4588","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279033","title":"Lexicon earns third $10M milestone payment from Novo Nordisk for LX9851","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279033?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:45","pubTimestamp":1787575521,"startTime":"0","endTime":"0","summary":"Lexicon (LXRX) announced that it has earned a third $10M milestone payment in 2026 from Novo Nordisk (NVO) following the achievement of a patient d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexicon-earns-third-10m-milestone-payment-from-novo-nordisk-for-lx9851-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexicon-earns-third-10m-milestone-payment-from-novo-nordisk-for-lx9851-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","LU1093756168.USD","BK4585","IE00BKVL7J92.USD","LXRX","NVOX","BK4599","NVOH","LU0154236417.USD","BK4139","BK4007","THNR","BK4588","OZEM","NVOC","IE00BZ1G4Q59.USD","LU1093756325.SGD","NVO","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194806564","title":"Hong Kong Memory Chip Stocks Plunge as Samsung Drops Nearly 8%, Leveraged Product Sinks 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194806564","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194806564?lang=en_us&edition=fundamental","pubTime":"2026-08-24 11:00","pubTimestamp":1787540434,"startTime":"0","endTime":"0","summary":"On August 24, memory chip stocks listed in Hong Kong experienced a broad decline, with the Southern Double Leveraged Samsung Electronics product plummeting 16%. Meanwhile, GigaDevice and VIA...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPXS","BK4543","RGTZ","NVOC","NVTC","SIMX","MULL","07347","VOO","ONTX","SPYM","NEBX","BK4007","TEUP","RAMZ","SSNLF","LITC","SH","09747","BK4585","RGTX","LITX","SPXU","MVV","NBIC","VRTL","SPYQ","LITG","SPYH","OSSL","UPRO","DISK","07747","RGTC","SPYU","DMAX","MUYY","BK4170","ALA","DRMP","VXUS","MIC","EMXC","DRAM","LITZ","NVOH","SAA","SPXL","LITU","RGYY","VRC","MUD","ETNG","SSO","MMAX","NVTX","DRMY","MUZ","SPY","HBMX","SPUU","MUG","DRAL","COZX","NBIL","SMAX","NVOX","MUU","LABX","NBIG","YSPY","SDS","KCAI","RGTU","SPDN","IVV","HIBL","FTXL","BK4588","XW","RAM","NBIZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188493561","title":"South Korea Sees Surge in Seized Illegal Weight-Loss Drugs, Tripling Last Year's Total in Just Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=1188493561","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188493561?lang=en_us&edition=fundamental","pubTime":"2026-08-24 10:04","pubTimestamp":1787537081,"startTime":"0","endTime":"0","summary":"Customs data released on Monday reveals that seizures of illegally imported weight-loss medications such as Wegovy and Mounjaro during the first half of this year have already surpassed the total for...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOX","NVOH","OZEM","NVOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661729161","title":"Novo Nordisk A/S Series B Stock Rises Friday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2661729161","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661729161?lang=en_us&edition=fundamental","pubTime":"2026-08-22 00:02","pubTimestamp":1787328120,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B advanced 1.6% to DKK300.85 Friday on what proved to be an overall favorable trading session for the stock market, with the OMX Nordic 40 Index rising 1.1% to 2,717.75.The company closed DKK109.10 below its 52-week high of DKK409.95, which the company reached on January 23, 2026.Trading volume was 3,754,463, compared to the 50-day average trading volume of 4,322,923.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","THNR","NVO","0QIU.UK","IE00BKVL7J92.USD","BK4599","BK4585","NVOC","BK4588","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4007","BK4532","NVOH","BK5011","PPH","LU0154236417.USD","LU1093756325.SGD","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286459","title":"Novonesis Expects Results from Weight-Loss Drug Supplement Study in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286459","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660286459?lang=en_us&edition=fundamental","pubTime":"2026-08-20 19:08","pubTimestamp":1787224108,"startTime":"0","endTime":"0","summary":"Novonesis expects results from weight-loss drug supplement study in 2027Aug 20 (Reuters)-Danish biosolutions maker NovonesisNSISb.COexpects results in the second half of 2027 from research with Novo N","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL8N44H0HA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","IE00BKVL7J92.USD","NVO","PPH","IE00BZ1G4Q59.USD","BK4109","BK4007","OZEM","LU0154236417.USD","NVZMY","NVOX","BK4532","THNR","BK4599","NVOH","BK4585","BK4588","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660333420","title":"Moderately bullish activity in Novo Nordisk with shares up 1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660333420","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660333420?lang=en_us&edition=fundamental","pubTime":"2026-08-20 02:05","pubTimestamp":1787162721,"startTime":"0","endTime":"0","summary":"Moderately bullish activity in Novo Nordisk (NVO), with shares up 60c, or 1.32%, near $46.31. Options volume running well above average with 83k co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-novo-nordisk-with-shares-up-1-32-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-novo-nordisk-with-shares-up-1-32-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVO","OZEM","BK4599","LU1093756325.SGD","BK4585","BK4532","IE00BZ1G4Q59.USD","THNR","NVOH","LU0154236417.USD","NVOX","LU1093756168.USD","BK4007","IE00BKVL7J92.USD","PPH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660226594","title":"Novo Nordisk Adds a New Early-Stage Obesity Drug to Its Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2660226594","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660226594?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:31","pubTimestamp":1787157069,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk A/S (NVO) is running a Phase 1 study called “An NNC6022-0004 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-adds-a-new-early-stage-obesity-drug-to-its-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-adds-a-new-early-stage-obesity-drug-to-its-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","NVOH","THNR","OZEM","PPH","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4599","LU1093756168.USD","LU1093756325.SGD","NVOX","BK4585","BK4007","NVO","IE00BKVL7J92.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660842442","title":"Novo Nordisk A/S Series B Stock Rises Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2660842442","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660842442?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:02","pubTimestamp":1787155320,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B advanced 1.0% to DKK299.45 Wednesday on what proved to be an overall positive trading session for the stock market, with the OMX Nordic 40 Index rising 0.1% to 2,687.50.This was the stock's second consecutive day of gains.The company closed DKK110.50 below its 52-week high of DKK409.95, which the company reached on January 23, 2026.Trading volume was 4,427,716, compared to the 50-day average trading volume of 4,379,076.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","LU1093756325.SGD","BK4585","LU1093756168.USD","BK4007","IE00BKVL7J92.USD","NVOX","NVO","BK4599","OZEM","THNR","IE00BZ1G4Q59.USD","BK4532","LU0154236417.USD","PPH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}